addressing the most challenging tumors

iOncologi’s multi-platform pipeline spans three first-in-class immunotherapeutic approaches designed to address the most intractable solid tumors, including glioblastoma (GBM), pediatric osteosarcoma, EGFR-positive and PSMA-positive malignancies. Together, these programs leverage proprietary delivery technologies, precision immune activation, and AI-guided antigen discovery to re-engineer the tumor–immune interface.

• Multi-Modality Innovation – Platforms span innate immune conditioning, targeted tumor immunotherapy, and autologous hematopoietic stem cell (HSC) immune reprogramming.
• Breaking Resistance – Specifically designed to overcome the immune suppression and checkpoint inhibitor resistance that define refractory tumors.
• Rapid Translation – Proprietary delivery systems enable efficient antigen presentation and potent immune priming without the need for extended patient-specific manufacturing in certain modalities.

• IONC101 – Currently in Phase I clinical evaluation in adult and pediatric GBM, with early translational data supporting activation of both innate and adaptive immune pathways and an acceptable safety profile.
• IONC201 – Advancing through IND-enabling studies targeting EGFR+ solid tumors, supported by preclinical data showing potent tumor-specific immune activation and synergy with checkpoint inhibitors.
• IONC301 – Currently in Phase I clinical evaluation in pediatric GBM, with robust preclinical mechanistic evidence of systemic immune reboot and enhanced anti-PD1 responsiveness in resistant GBM models.